Healthcare Analysts, along with a patent lawyer, discuss Madrigal Pharmaceuticals’ (MDGL) Resmetirom and Verona Pharma’s (VRNA) Ensifentrine patent on an Analyst/Industry conference call to be held on March 24.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MDGL:
- Piper Sandler healthcare analysts to hold an analyst/industry conference call
- This ETF Has 67% Upside Potential, According to Analysts
- Madrigal Pharmaceuticals price target raised to $336 from $296 at Canaccord
- Madrigal Pharmaceuticals price target raised to $300 from $250 at Oppenheimer
- Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results